Apr 25,2022

Accuracy of a Seventh-Generation Continuous Glucose Monitoring System in Children and Adolescents With Type 1 Diabetes

Accuracy of a seventh-generation “G7” continuous glucose monitoring (CGM) system was evaluated in children and adolescents with type 1 diabetes (T1D).

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Apr 26,2022

Outcomes in Pump- and CGM-Baseline Use Subgroups in the International Diabetes Closed-Loop (iDCL) Trial

Researchers investigated the potential benefits of automated insulin delivery (AID) among individuals with type 1 diabetes (T1D) in sub-populations of baseline device use determined by continuous glucose monitor (CGM) use status and insulin delivery via multiple daily injections (MDI) or insulin pump.

CLINICAL STUDY

#cgm

#insulin pump

#closed loop

View Analyst & Ambassador Comments
Go to original news
Apr 26,2022

Expert Recommendations for Using Time-in-Range and Other Continuous Glucose Monitoring Metrics to Achieve Patient-Centered Glycemic Control in People With Diabetes

The objective of the present review is to provide practical insights to quick interpretation of patient-centered metrics based on flash glucose monitoring data, as well as showing some visual examples of common clinical situations and giving practical recommendations for their management.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Apr 27,2022

Abbott Diabetes Care, CamDiab and Ypsomed Unveil New Automated Insulin Delivery Partnership For People With Diabetes

Abbott Diabetes Care, CamDiab and Ypsomed today announced that they are partnering to develop and commercialize an integrated automated insulin delivery (AID) system to help lessen the burden of round-the-clock diabetes management for people with diabetes. The initial focus of the partnership will be in European countries. The new integrated AID system is being designed to connect Abbott's FreeStyle Libre 3 sensor to CamDiab's CamAPS FX mobile app, which connects with Ypsomed's mylife YpsoPump – creating an automated process to deliver insulin based on real-time glucose data.

COLLABORATION PARTNERSHIP

#connected device

#cgm

#closed loop

View Analyst & Ambassador Comments
Go to original news
Apr 27,2022

Welldoc Presents Data Indicating Continuous Glucose Monitoring (CGM) Combined with a Digital Health Solution Leads to Significant Improvements in Glycemic Outcomes

Welldoc®, a digital health leader revolutionizing chronic care, today announced the presentation of data at the 15th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD), evaluating how the combination of real-time CGM (rtCGM) with a digital health solution impacts glucose control for individuals with Type 2 diabetes not treated with insulin.

CLINICAL STUDY

#cgm

#mobile app

View Analyst & Ambassador Comments
Go to original news
Apr 28,2022

Dexcom Reports First Quarter 2022 Financial Results

DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended March 31, 2022. First Quarter 2022 Financial Highlights: Revenue grew 25% versus the same quarter of the prior year to $628.8 million on a reported basis and 22% on an organic 1 basis.

#cgm

View Analyst & Ambassador Comments
Go to original news
Apr 28,2022

NEW ANALYSIS SHOWS THAT Abbott Diabetes Care'S FREESTYLE LIBRE® SYSTEM PROVIDES SIMILAR AND SUSTAINED REDUCTIONS IN GLUCOSE LEVELS FOR PEOPLE WITH BOTH TYPE 1 AND TYPE 2 DIABETES

Abbott Diabetes Care (NYSE: ABT) today announced results from a new meta-analysis of 75 real-world, observational studies demonstrating that its FreeStyle® Libre system provides significant reductions in glycated hemoglobin (HbA1c) that are sustained up to 24 months in adults with both type 1 and type 2 diabetes.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Apr 29,2022

Dexcom study shows strong accuracy for next-gen G7 CGM in pediatric T1D patients

Dexcom (Nasdaq:DXCM) published new data highlighting the accuracy of the next-generation G7 continuous glucose monitor in children. San Diego-based Dexcom’s study, published in the Journal of Diabetes and Scientific Technology, evaluated the G7 CGM in children and adolescents with type 1 diabetes. G7, which last month won CE mark approval, remains under FDA 510(k) review.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
May 03,2022

CGMs, insulin pumps and more: the biggest diabetes news to come out of ATTD 2022

All kinds of technologies were on display at the Advanced Technologies & Treatments for Diabetes (ATTD) conference in Barcelona last week. From continuous glucose monitoring (CGM) to automated insulin delivery, with plenty in between, a number of companies shared positive data for their diabetes offerings. Here are five of the biggest stories to come out.

#cgm

#insulin pump

#insulin pen

View Analyst & Ambassador Comments
Go to original news
May 03,2022

Evaluating Factors Associated With Continuous Glucose Monitoring Utilization With the Type 1 Diabetes Exchange Registry

This study evaluates socioeconomic and demographic metrics associated with CGM use.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Subscribe to CGM